Conditions: Advanced Non Small Cell Lung Cancer (NSCLC)
Keywords: Non-small cell lung carcinoma (NSCLC) treatment of lung cancer after first metastasis lung cancer lung adenocarcinoma Squamous cell lung carcinoma Large-cell lung carcinoma Non small cell lung carcinoma Non small cell lung cancer Non-small cell lung cancer NSCLC Large cell lung carcinoma Large cell lung cancer HSP90 AUY922 Pemetrexed Docetaxel EGFR TKI EGFR mutations
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 59
Healthy volunteers: no

Brief summary:
The purpose of this study was to determine if AUY922 had superior efficacy when compared to chemotherapy agents docetaxel or pemetrexed in patients whose tumor had EGFR mutations.

The primary purpose of this study was to compare the efficacy of AUY922, when administered i.v. on a once-weekly schedule at 70 mg/m2, versus docetaxel or pemetrexed in adult patients with advanced NSCLC, whose tumors harbored EGFR activating mutations, and had developed resistance to EGFR TKI.

Detailed description:

Arms:
arm 1: Participants were assigned to one of two treatment arms in a ratio of 1:1. This was the investigational drug arm.

AUY922 was to be administered weekly. arm 2: Participants were assigned to one of two treatment arms in a ratio of 1:1. This was the control arm drug arm.

Pemetrexed or docetaxel was to be was to be given once every three weeks.

Interventions: intervention 1: AUY922 intervention 2: Docetaxel intervention 3: Pemetrexed
Intervention descriptions: intervention 1: AUY922 was to be given by i.v. once weekly at 70 mg/m2 until disease progression, death or any other reason for discontinuation from study treatment. intervention 2: Docetaxel was to be given i.v. once every 3 weeks at 75 mg/m2 until progression or unacceptable toxicity intervention 3: Pemetrexed was to be given once every 3 weeks at 500 mg/m2 until progression or unacceptable toxicity

Protocol document: